Phase 3 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have geographic atrophy (GA) of the central part of the eye (the macula) caused by age-related macular degeneration (AMD)
• People whose GA affects an area of a specific size — not too small and not too large — as measured during screening (confirm with trial site)
• People whose vision in the study eye is at a certain level or better, roughly equivalent to reading the 20/80 line on a standard eye chart
• People whose eye is clear enough inside, with pupils that can dilate adequately, to allow good quality eye imaging
• People who are willing and able to attend clinic visits and follow all study procedures, including completing a required series of meningococcal and pneumococcal vaccinations

Who may not be able to join:

• People whose GA is caused by something other than AMD, such as Stargardt disease, cone rod dystrophy, or damage from medications like hydroxychloroquine
• People who have or have had abnormal blood vessel growth or fluid leakage in either eye of a specific type (confirm with trial site)
• People who have received injections into the eye for any reason, unless those injections were certain approved or investigational treatments given at least 6 months before joining the trial
• People who have had eye surgery other than cataract removal or certain minor glaucoma procedures, or who had those procedures less than 3 months before joining the trial
• People who have another progressive eye condition in the study eye — such as diabetic retinopathy, macular swelling, poorly controlled glaucoma, or a macular hole — that could affect central vision
• People whose eye has cloudiness or abnormalities (such as advanced cataracts or corneal problems) that would interfere with eye examinations
• People who have used or are currently using a systemic complement inhibitor medication within the 6 months before joining the trial (confirm with trial site for what this includes)
• People who have had a solid organ transplant or bone marrow transplant
• People who have used high-dose oral or injected corticosteroid medications (such as prednisone at certain doses) for more than 14 days within the 30 days before their first screening visit
• People who have used certain immune-suppressing medications (other than steroids) within the 12 months before joining the trial, or who are likely to need such medications during the study
• People who do not meet the required meningococcal or pneumococcal vaccination requirements for the study
• People who are found to be carriers of a specific bacteria called Neisseria meningitidis, detected during screening
• People whose blood sugar control measure (HbA1c) is at or above a certain level during screening, suggesting poorly controlled diabetes

Important: Always verify eligibility with the trial site directly before applying.